<strong>From Curcumin Toward Treatment of Alzheimer’s Disease: Some Thoughts on New Drug Discovery</strong>

Abstract

Abstract:During the last two decades， the story of vigorous curcumin R&D from activity assay to pre-clinical and clinical trials for Alzheimer’s disease and to final failure represents a chaotic thinking on pharmaceutical drug development. The research goals of pharmacologically involved compounds are usually as follows: to observe and record the activity spectrum of synthesized or isolated molecules; to advance drug candidate development based on activity，pharmacodynamic and pharmacokinetic data; to study the mechanism of action of druggable compound; and to participate in the basic biomedical research with the compound as a tool after the mechanism has been well known. Therefore， to avoid the waste of research resources and time，it is necessary for people to set up a clear goal，compare the chemical structures and exhaustively review the literature before a compound is going to be studied.

Key words:curcumin,Alzheimer&,rsquo,s disease,activity,pharmacodynamics,mechanism,druggability

CLC Number:

R964

YIN Ming, WANG Ze-jian, ZHAO Wen-juan.From Curcumin Toward Treatment of Alzheimer’s Disease: Some Thoughts on New Drug Discovery[J]. Acta Neuropharmacologica, 2014, 4(2): 1-7.

References

[1] Baell J & Walters M. Chemistry: Chemical con artists foil drug discovery [J]. Nature, 2014, 513: 481-483.

[2] Singh S. From exotic spice to modern drug [J]? Cell, 2007, 130: 765-768.

[3] Aggarwal BB & Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets [J]. Trends Pharmacol Sci, 2009, 30: 85-94.

[4] Priyadarsini KI. Chemical and structural features influencing the biological activity of curcumin [J]. Curr Pharm Des, 2013, 19: 2093-2100.

[5] Brondino N, Re S, Boldrini A, Cuccomarino A, Lanati N, Barale F, Politi P. Curcumin as a therapeuric agent in dementia: a mini systemic review of human studies [J]. Sci World J, 2014:174282.

[6] Ireson C,Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, Farmer PB, Steward WP, Gescher AJ. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine [J]. Cancer Epidemiol Biomark Prev, 2002, 11: 105-111.

[7] Ji H & Shen L. Can improving bioavailability improve the bioactivity of curcumin [J]? Trends Pharmacol Sci, 2014, 36: 265-266.

[8] Baell J & Holloway G. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays [J]. J Med Chem, 2010, 53: 2719-2740.

[9] Baell JB. Observations on screening-based research and some concerning trends in the literature [J]. Future Med Chem, 2010, 2: 1529-1546.

[10] Hu Y & Bajorath J. What is the likelihood of an active compound to be promiscuous? Systematic assessment of compound promiscuity on the basis of PubChem confirmatory bioassay data [J]. AAPS J, 2013, 15: 808-815.

[11] Voss ME , Carter PH, Tebben AJ, Scherle PA, Brown GD, Thompson LA, Xu M, Lo YC, Yang G, Liu RQ, Strzemienski P, Everlof JG, Trzaskos JM, Decicco CP. Both 5-arylidene-2-thioxodihydropyrimidine-4,6(1H,5H)-diones and 3-thioxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-ones are light-dependent tumor necrosis factor-alpha antagonists [J]. Bioorg Med Chem Lett, 2003, 13: 533-538.

[12] Alpers DH. The potential use of curcumin in management of chronic disease: too good to be true [J]? Curr Opin Gastroenterol, 2008, 24: 173-175.

[13] Vane JR. Prostaglandins as mediators of inflammation [J]. Adv Prostaglandin Thromboxane Res, 1976, 2: 791-801.

[14] Ganellin CR. Personal reflections on Sir James Black (1924-2010) and histamine [J]. Inflamm Res, 2011, 60: 103-110.

[15] Black J. Pioneers in cardiology: Sir James Black, MB, ChB, FRS, FRCP. Interview by Mark Nicholls [J]. Circulation, 2008, 117: f47-48.

From Curcumin Toward Treatment of Alzheimer’s Disease: Some Thoughts on New Drug Discovery

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

[1]	XIE bin, HUANG Zhi-yuan, LIN Duo-duo, YANG Fu-long, XIE Yi-bin.Effect of Acupuncture Combined with Medicine on Depressive Symptoms of Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 5-8.
[2]	SUN Li-cong, ZHANG Dan-shen.Research Progress on Potential Treatment of Alzheimer’s Disease with Alkaloids[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 33-37.
[3]	WANG Si-yi, LI Xian-xiang, LIU Yi-zhou, DU Shuang, GE Chao, LIU Si-si.Current Situation and Prospect of Alzeimer’s Disease Treatment[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 38-42.
[4]	ZHAO Yu-wei, ZHEN Yan-jie, DAI Yue-ying, SHEN Li-xia.Study on the Neuroprotective Mechanism of Quercetin in Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 55-64.
[5]	HAI Ji-tao, LUO Huan-min.Progress on the Relationship between Pathogenic Microorganisms and Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(4): 58-64.
[6]	ZHANG Hao-ting, SONG Gui-qin, CUI Ruo-tong, HAO Min, WANG Wen-dong.Mining Target Genes of Alzheimer’s Disease Associated with Biological Clock by Bioinformatics Analysis[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 1-7.
[7]	YANG Xu-hua, DU Shuang, SHEN Li-xia, HAO Jun-rong.Research Progress in Drug Treatment of Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 47-53.
[8]	ZHONG Wei-quan, LIU You-bo, ZHOU Cai-jie, ZHENG Yin-ju, WU Ming-li, LIANG Min, ZHANG Yuan-yuan.Study on the Protective Mechanism of Effective Components of Ginseng on Osteoarthritis Based on Network Pharmacology[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(1): 10-16.
[9]	ZHANG Jian-mei, ZHANG Dan-shen.Research on Local Hemostatic Materials and Mechanisms[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(1): 17-19.
[10]	ZHEN Yan-jie, GUO Tong-lin, ZHAO Yu-wei, SHEN Li-xia.Study Progress on Phytoestrogen-Mediated Mitochondrial Pathway’s Neuroprotective Effects in Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(1): 40-46.
[11]	XIA Xiao-wen，SONG Chun-hong，QIAO Ming-qi, et al.Research Progress on the Mechanism of PMDD[J]. Acta Neuropharmacologica, 2019, 9(6): 36-40.
[12]	LIANG Yu-fei，ZHANG Xin-xin，ZHAO Li-yan，et al.Discussed the Application of Curcumin Combined with Piperine Based on the Metabolic Characteristics of Curcumin[J]. Acta Neuropharmacologica, 2019, 9(6): 47-57.
[13]	SONG Yi-lei，HOU Xue-qin，HAO Ji-fu.Advances in Research on Modern Pharmacological Effects and Clinical Application of Cnidium[J]. Acta Neuropharmacologica, 2019, 9(6): 58-63.
[14]	YANG Jing，YUAN Wen-ying.Toxoplasma Infection on Nerve Tissue Damage and Its Mechanism through the Blood-Brain Barrier[J]. Acta Neuropharmacologica, 2019, 9(5): 40-43.
[15]	YANG-Lin，AI-Jing.Research Progress of Brain-Derived Estrogen in Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2019, 9(5): 50-64.